LYNDA TRAN: Open Payments
NPI 1942776240 · HUNTINGTON BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,586 in 41 payments from 12 companies in 2025. Trend: 2023 $2,959 · 2024 $5,109 · 2025 $2,586
Food & beverage: $2,586
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 13 | $794 |
| E.R. Squibb & Sons, L.L.C. | 7 | $429 |
| Astellas Pharma US Inc | 4 | $303 |
| Exelixis Inc. | 5 | $227 |
| Merck Sharp & Dohme LLC | 3 | $156 |
| Novartis Pharmaceuticals Corporation | 2 | $135 |
| Agios Pharmaceuticals, Inc. | 1 | $125 |
| GlaxoSmithKline, LLC. | 1 | $120 |
| Caris MPI, Inc. | 1 | $114 |
| Janssen Scientific Affairs, LLC | 1 | $109 |
Products named: RYBREVANT, OPDIVO, CABOMETYX, ERLEADA, Vyloy, LYNPARZA, PYRUKYND, Padcev.
Industry payments across CA — which companies pay providers there.
